GammaCan International and Life Therapeutics on Tuesday signed a term sheet to collaborate to jointly develop VitiGam, an innovative, anti-cancer product designed to target metastatic malignant melanoma patients with Stage III and IV disease.
Advanced stage melanoma represents a large unmet medical need as there currently are no safe and effective therapies available to patients, the companies said.
The partners will share the costs and expenses relating to the development, supply, collection, manufacture, storage and commercialization of VitiGam, as well as their respective portion in any proceeds resulting of the collaboration. Life Therapeutics will also supply plasma to GammaCan for the project.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>